As PDGFs and VEGF-A have been shown to be regulated by TGF-β1 27, the concurrent reduction in TGF-β1, PDGF-AA and PDGF-BB, and VEGF-A suggests an important interplay among these factors in cancer patients treated with TRC105. This evidence concerns the gene VEGFA and cancer.